Observational claims analysis shows reduced urinary toxicities in prostate patients using perirectal spacers, suggesting clinical benefits.
In this large observational claims-based study, perirectal spacer use during prostate radiotherapy was associated with reduced short-term urinary toxicities and healthcare costs, but not with a statistically significant difference in rectal toxicity, the primary FDA-approved indication.
No takes yet. Share an insight, caveat, or question.
Palencia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: